Other
Immune-Related Adverse Events
1
Pipeline Programs↗
6
Active Trials↗
1
Companies Involved↗
Immune-related Adverse Events is an early-stage landscape with 1 program across 1 company. The most active players are Roche.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Trial Status
11
clinical trials
Recruiting4 · 36%
Unknown status3 · 27%
Completed2 · 18%
Active, not recruiting1 · 9%
Not yet recruiting1 · 9%
Clinical Trials
Trial Activity
11 trials
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
Recruiting·—·Phase 2·NCT06470971·40 enrolled
Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment
Recruiting·—·N/A·NCT05813418·150 enrolled
Brodalumab in the Treatment of Immune-Related Adverse Events
Recruiting·—·Phase 1·NCT06673329·11 enrolled
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
Active, not recruiting·—·Phase 2·NCT04375228·8 enrolled
Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events
Not yet recruiting·—·Phase 1·NCT07694414·25 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)